The Experts below are selected from a list of 237 Experts worldwide ranked by ideXlab platform
Yongsheng Wang - One of the best experts on this subject based on the ideXlab platform.
-
the lymphatic drainage pattern of internal mammary sentinel lymph node identified by small particle radiotracer 99mtc Dextran 40 in breast
Cancer Research and Treatment, 2019Co-Authors: Guoren Yang, Binbin Cong, Yongsheng WangAbstract:PURPOSE: The purpose of this study was to detect the lymphatic drainage pattern of internal mammary area and verify the concept of internal mammary sentinel lymph node (IM-SLN) in breast. Materials and Methods: A small particle radiotracer (99mTc-Dextran 40) was prepared and tested. 99mTc-Dextran 40 was injected into intraparenchyma at the sound breast by a modified radiotracer injection technique. Subsequently, dynamic single-photon emission computed tomography (SPECT), computed tomography (CT), and SPECT/CT combination images were performed to identify the radioactive lymph vessels and internal mammary lymph nodes (IMLNs). The direction of lymph drainage and the location of the IMLNs were identified in the SPECT/CT imaging. RESULTS: The radiochemical purity of 99mTc-Dextran 40 was > 95%. 99mTc-Dextran 40 could drainage into first, second, and third lymph node and the radioactive lymph node could be detected by the γ detector in the animal experiment. After 99mTc-Dextran 40 injecting into intraparenchyma, 50.0% cases (15/30) were identified the drainage lymphatic vessels and radioactive IMLNs by SPECT. The drainage lymphatic vessel was found from injection point to the first IMLN (IM-SLN) after 10.5±0.35 minutes radiotracer injection, and then 99mTc-Dextran 40 was accumulated into the IM-SLN. The combination imaging of SPECT/CT showed the second IMLN received the lymph drainage from the IM-SLN. The lymphatic drainage was step by step in the internal mammary area. CONCLUSION: The lymph was identified to drain from different regions of the breast to IM-SLN, and then outward from IM-SLN to other IMLN consecutively. It demonstrated the concept of the IM-SLN and provided more evidences for the application of internal mammary sentinel lymph node biopsy.
-
the lymphatic drainage pattern of internal mammary sentinel lymph node identified by small particle radiotracer 99mtc Dextran 40 in breast
Cancer Research and Treatment, 2019Co-Authors: Guoren Yang, Binbin Cong, Yongsheng WangAbstract:PURPOSE: The purpose of this study was to detect the lymphatic drainage pattern of internal mammary area and verify the concept of internal mammary sentinel lymph node (IM-SLN) in breast. Materials and Methods: A small particle radiotracer (99mTc-Dextran 40) was prepared and tested. 99mTc-Dextran 40 was injected into intraparenchyma at the sound breast by a modified radiotracer injection technique. Subsequently, dynamic single-photon emission computed tomography (SPECT), computed tomography (CT), and SPECT/CT combination images were performed to identify the radioactive lymph vessels and internal mammary lymph nodes (IMLNs). The direction of lymph drainage and the location of the IMLNs were identified in the SPECT/CT imaging. RESULTS: The radiochemical purity of 99mTc-Dextran 40 was > 95%. 99mTc-Dextran 40 could drainage into first, second, and third lymph node and the radioactive lymph node could be detected by the γ detector in the animal experiment. After 99mTc-Dextran 40 injecting into intraparenchyma, 50.0% cases (15/30) were identified the drainage lymphatic vessels and radioactive IMLNs by SPECT. The drainage lymphatic vessel was found from injection point to the first IMLN (IM-SLN) after 10.5±0.35 minutes radiotracer injection, and then 99mTc-Dextran 40 was accumulated into the IM-SLN. The combination imaging of SPECT/CT showed the second IMLN received the lymph drainage from the IM-SLN. The lymphatic drainage was step by step in the internal mammary area. CONCLUSION: The lymph was identified to drain from different regions of the breast to IM-SLN, and then outward from IM-SLN to other IMLN consecutively. It demonstrated the concept of the IM-SLN and provided more evidences for the application of internal mammary sentinel lymph node biopsy.
Guoren Yang - One of the best experts on this subject based on the ideXlab platform.
-
the lymphatic drainage pattern of internal mammary sentinel lymph node identified by small particle radiotracer 99mtc Dextran 40 in breast
Cancer Research and Treatment, 2019Co-Authors: Guoren Yang, Binbin Cong, Yongsheng WangAbstract:PURPOSE: The purpose of this study was to detect the lymphatic drainage pattern of internal mammary area and verify the concept of internal mammary sentinel lymph node (IM-SLN) in breast. Materials and Methods: A small particle radiotracer (99mTc-Dextran 40) was prepared and tested. 99mTc-Dextran 40 was injected into intraparenchyma at the sound breast by a modified radiotracer injection technique. Subsequently, dynamic single-photon emission computed tomography (SPECT), computed tomography (CT), and SPECT/CT combination images were performed to identify the radioactive lymph vessels and internal mammary lymph nodes (IMLNs). The direction of lymph drainage and the location of the IMLNs were identified in the SPECT/CT imaging. RESULTS: The radiochemical purity of 99mTc-Dextran 40 was > 95%. 99mTc-Dextran 40 could drainage into first, second, and third lymph node and the radioactive lymph node could be detected by the γ detector in the animal experiment. After 99mTc-Dextran 40 injecting into intraparenchyma, 50.0% cases (15/30) were identified the drainage lymphatic vessels and radioactive IMLNs by SPECT. The drainage lymphatic vessel was found from injection point to the first IMLN (IM-SLN) after 10.5±0.35 minutes radiotracer injection, and then 99mTc-Dextran 40 was accumulated into the IM-SLN. The combination imaging of SPECT/CT showed the second IMLN received the lymph drainage from the IM-SLN. The lymphatic drainage was step by step in the internal mammary area. CONCLUSION: The lymph was identified to drain from different regions of the breast to IM-SLN, and then outward from IM-SLN to other IMLN consecutively. It demonstrated the concept of the IM-SLN and provided more evidences for the application of internal mammary sentinel lymph node biopsy.
-
the lymphatic drainage pattern of internal mammary sentinel lymph node identified by small particle radiotracer 99mtc Dextran 40 in breast
Cancer Research and Treatment, 2019Co-Authors: Guoren Yang, Binbin Cong, Yongsheng WangAbstract:PURPOSE: The purpose of this study was to detect the lymphatic drainage pattern of internal mammary area and verify the concept of internal mammary sentinel lymph node (IM-SLN) in breast. Materials and Methods: A small particle radiotracer (99mTc-Dextran 40) was prepared and tested. 99mTc-Dextran 40 was injected into intraparenchyma at the sound breast by a modified radiotracer injection technique. Subsequently, dynamic single-photon emission computed tomography (SPECT), computed tomography (CT), and SPECT/CT combination images were performed to identify the radioactive lymph vessels and internal mammary lymph nodes (IMLNs). The direction of lymph drainage and the location of the IMLNs were identified in the SPECT/CT imaging. RESULTS: The radiochemical purity of 99mTc-Dextran 40 was > 95%. 99mTc-Dextran 40 could drainage into first, second, and third lymph node and the radioactive lymph node could be detected by the γ detector in the animal experiment. After 99mTc-Dextran 40 injecting into intraparenchyma, 50.0% cases (15/30) were identified the drainage lymphatic vessels and radioactive IMLNs by SPECT. The drainage lymphatic vessel was found from injection point to the first IMLN (IM-SLN) after 10.5±0.35 minutes radiotracer injection, and then 99mTc-Dextran 40 was accumulated into the IM-SLN. The combination imaging of SPECT/CT showed the second IMLN received the lymph drainage from the IM-SLN. The lymphatic drainage was step by step in the internal mammary area. CONCLUSION: The lymph was identified to drain from different regions of the breast to IM-SLN, and then outward from IM-SLN to other IMLN consecutively. It demonstrated the concept of the IM-SLN and provided more evidences for the application of internal mammary sentinel lymph node biopsy.
Binbin Cong - One of the best experts on this subject based on the ideXlab platform.
-
the lymphatic drainage pattern of internal mammary sentinel lymph node identified by small particle radiotracer 99mtc Dextran 40 in breast
Cancer Research and Treatment, 2019Co-Authors: Guoren Yang, Binbin Cong, Yongsheng WangAbstract:PURPOSE: The purpose of this study was to detect the lymphatic drainage pattern of internal mammary area and verify the concept of internal mammary sentinel lymph node (IM-SLN) in breast. Materials and Methods: A small particle radiotracer (99mTc-Dextran 40) was prepared and tested. 99mTc-Dextran 40 was injected into intraparenchyma at the sound breast by a modified radiotracer injection technique. Subsequently, dynamic single-photon emission computed tomography (SPECT), computed tomography (CT), and SPECT/CT combination images were performed to identify the radioactive lymph vessels and internal mammary lymph nodes (IMLNs). The direction of lymph drainage and the location of the IMLNs were identified in the SPECT/CT imaging. RESULTS: The radiochemical purity of 99mTc-Dextran 40 was > 95%. 99mTc-Dextran 40 could drainage into first, second, and third lymph node and the radioactive lymph node could be detected by the γ detector in the animal experiment. After 99mTc-Dextran 40 injecting into intraparenchyma, 50.0% cases (15/30) were identified the drainage lymphatic vessels and radioactive IMLNs by SPECT. The drainage lymphatic vessel was found from injection point to the first IMLN (IM-SLN) after 10.5±0.35 minutes radiotracer injection, and then 99mTc-Dextran 40 was accumulated into the IM-SLN. The combination imaging of SPECT/CT showed the second IMLN received the lymph drainage from the IM-SLN. The lymphatic drainage was step by step in the internal mammary area. CONCLUSION: The lymph was identified to drain from different regions of the breast to IM-SLN, and then outward from IM-SLN to other IMLN consecutively. It demonstrated the concept of the IM-SLN and provided more evidences for the application of internal mammary sentinel lymph node biopsy.
-
the lymphatic drainage pattern of internal mammary sentinel lymph node identified by small particle radiotracer 99mtc Dextran 40 in breast
Cancer Research and Treatment, 2019Co-Authors: Guoren Yang, Binbin Cong, Yongsheng WangAbstract:PURPOSE: The purpose of this study was to detect the lymphatic drainage pattern of internal mammary area and verify the concept of internal mammary sentinel lymph node (IM-SLN) in breast. Materials and Methods: A small particle radiotracer (99mTc-Dextran 40) was prepared and tested. 99mTc-Dextran 40 was injected into intraparenchyma at the sound breast by a modified radiotracer injection technique. Subsequently, dynamic single-photon emission computed tomography (SPECT), computed tomography (CT), and SPECT/CT combination images were performed to identify the radioactive lymph vessels and internal mammary lymph nodes (IMLNs). The direction of lymph drainage and the location of the IMLNs were identified in the SPECT/CT imaging. RESULTS: The radiochemical purity of 99mTc-Dextran 40 was > 95%. 99mTc-Dextran 40 could drainage into first, second, and third lymph node and the radioactive lymph node could be detected by the γ detector in the animal experiment. After 99mTc-Dextran 40 injecting into intraparenchyma, 50.0% cases (15/30) were identified the drainage lymphatic vessels and radioactive IMLNs by SPECT. The drainage lymphatic vessel was found from injection point to the first IMLN (IM-SLN) after 10.5±0.35 minutes radiotracer injection, and then 99mTc-Dextran 40 was accumulated into the IM-SLN. The combination imaging of SPECT/CT showed the second IMLN received the lymph drainage from the IM-SLN. The lymphatic drainage was step by step in the internal mammary area. CONCLUSION: The lymph was identified to drain from different regions of the breast to IM-SLN, and then outward from IM-SLN to other IMLN consecutively. It demonstrated the concept of the IM-SLN and provided more evidences for the application of internal mammary sentinel lymph node biopsy.
A R Naylor - One of the best experts on this subject based on the ideXlab platform.
-
Dextran 40 stimulates resting platelets and binds more avidly to activated platelets
British Journal of Surgery, 2000Co-Authors: Paul D Hayes, Helen Box, Samantha Tull, P R F Bell, Alison H Goodall, A R NaylorAbstract:Background: A programme of monitoring and treatment with low-dose 10 per cent Dextran-40 (20 ml h−1) can successfully prevent thrombotic occlusion of the carotid artery after endarterectomy. This is a clinically effective treatment, over 500 CEAs have been performed with no thrombotic strokes, but little is known about the mechanism by which low-dose Dextran-40 affects platelet-rich thrombus formation. Methods: In study 1, platelets from ten patients undergoing CEA were collected in a standardized manner. The response to therapeutic doses of Dextran-40 was assessed in vitro using whole-blood flow cytometric analysis of fibrinogen binding in response to adenosine 5′-diphosphate (ADP) and thrombin. Platelet aggregation in response to ADP and collagen was recorded. In study 2, blood collected from ten normal subjects was incubated with fluorescently labelled Dextran-40 and binding was measured using flow cytometry. In these experiments blood was either first incubated for 10 min with the FITC–Dextran-40 and then activated with thrombin 0·4 units ml−1 or activated with thrombin 0·4 units ml−1 for 10 min before incubation with FITC–Dextran-40. Results: In study 1, reincubation of the patients' blood with Dextran-40 increased fibrinogen binding to resting platelets by 352 per cent (P < 0·05) and to ADP-stimulated platelets by 39 per cent (P < 0·05). Dextran-40 also increased fibrinogen binding in response to thrombin although this difference was not significant (P = 0·12), and increased platelet aggregation in response to ADP (48 per cent) and collagen (32 per cent) (P < 0·05 for both). In study 2, fluorescently labelled Dextran-40 bound to the surface of resting platelets from normal subjects in a dose-dependent manner, and caused platelet activation, as measured by increased P-selectin expression. Incubation with Dextran followed by activation caused a 28 per cent increase in Dextran binding; however, if the platelets were activated first and then exposed to Dextran the binding increased 94 per cent (P = 0·001). Conclusion: Low-dose Dextran-40 is very effective in preventing thromboembolic complications after CEA. However, in vitro, Dextran-40 has a direct stimulatory effect on platelets. Dextran-40 binds to platelets and shows preferential binding to activated, compared with resting, platelets. Dextran may exert a beneficial antiplatelet/antithrombotic effect in vivo by inhibiting the recruitment of activated platelets to a growing thrombus. © 2000 British Journal of Surgery Society Ltd
-
transcranial doppler directed Dextran 40 therapy is a cost effective method of preventing carotid thrombosis after carotid endarterectomy
European Journal of Vascular and Endovascular Surgery, 2000Co-Authors: Paul D Hayes, P R F Bell, A J Lloyd, Nikki Lennard, Jane Wolstenholme, N J M London, A R NaylorAbstract:Abstract Objectives perioperative stroke reduces the clinical effectiveness of carotid endarterectomy (CEA). Postoperative thrombotic stroke may be reduced in incidence by the use of transcranial Doppler-directed Dextran-40 therapy. This programme requires the purchase of additional equipment and employment of more staff. This study examined whether this additional financial outlay was cost-effective in terms of saving expenditure by preventing postoperative thrombotic stroke. Materials and methods data was collected prospectively on a series of 600 consecutive CEAs. The costs of the monitoring programme were analysed over 1- and 5-year periods. Formulae were derived allowing other units to calculate whether this technique will be cost-effective for them. Results after the introduction of TCD monitoring the postoperative thrombotic stroke rate fell from 2.7% to 0% (8 strokes prevented). Our local unit cost for the treatment of stroke was £25 702. After allowing for the additional costs of the monitoring programme, we calculate that postoperative TCD has saved £171 393. Conclusions postoperative TCD monitoring is a clinically effective and also cost-effective method of reducing the stroke rate associated with CEA. For units performing more than 50 CEAs per year who experience occasional postoperative carotid thrombosis, its introduction should be considered.
Yurren Kuo - One of the best experts on this subject based on the ideXlab platform.
-
the outcome of prostaglandin e1 and Dextran 40 compared to no antithrombotic therapy in head and neck free tissue transfer analysis of 1 351 cases in a single center
Microsurgery, 2012Co-Authors: Francesco M G Riva, Yenchou Chen, Ngianchye Tan, Paoyuan Lin, Yunta Tsai, Hsuehwen Chang, Yurren KuoAbstract:Free tissue transfer has become a popular technique for soft tissue defect reconstruction in head and neck cancer ablation. Although high success rates and good reliability of free flaps are proven, microvascular thrombosis is still the most critical issue for microsurgeons. Pharmacological antithrombotic agents are widely used but their efficacy is still debated. In this study, we analyzed whether prostaglandin-E1 (PGE1) and Dextran-40 can improve the outcomes compared to no antithrombotic therapy at all. We retrospectively reviewed 1,351 free flaps performed for head and neck reconstruction after cancer ablation. Three groups defined were 232 flaps received PGE1, 283 flaps received Dextran-40, and 836 received no antithrombotic therapy. The demographics of these three groups indicated no statistical differences. The results showed that flap survival revealed no significant difference among PGE1, Dextran-40, and control group (P = 0.734). There was a tendency to hematomas in PGE1 group (P = 0.056) when compared with other two groups. Dextran-40 significantly increased flap failure rate in high-risk patients with diabetes mellitus (P = 0.006) or hypertension (P = 0.003), when compared with PGE1 and control group. These results revealed antithrombotic therapy with PGE1 and Dextran-40 do not determine a significant improvement in flap survival.